Bayer's Stivarga endorsed for gastrointestinal stromal tumors
FRANKFURT (Reuters) - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Health